Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 36 Neoplasm Metastasis 12 Neoplasms 10 Colorectal Neoplasms 5 Thyroid Neoplasms 4 Thyroid Cancer, Papillary 4 Multiple Myeloma 4 Leukemia, Hairy Cell 4 Hematologic Neoplasms 4 Skin Neoplasms 3 Pancreatic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Breast Neoplasms 3 Thyroid Carcinoma, Anaplastic 2 Recurrence 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Lymphoma, Non-Hodgkin 2 Brain Neoplasms 2 Thyroid cancer, follicular 1 Thrombocytosis 1 Sarcoma, Clear Cell 1 Sarcoma 1 Relapsed Pediatric Solid Tumor 1 Rare Tumour 1 Rare Tumor 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumor × Vemurafenib × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡